

**NEUROLOGY REFERRAL FORM**

**Y Medical Associates**  
**Fax : 855-838-0623**  
**Phone: 800-447-7558**



Date: \_\_\_\_\_

Current Patient     New Patient

**Patient Information**

Patient Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Home Phone: \_\_\_\_\_  
 Cell Phone: \_\_\_\_\_  
 Alternate Phone: \_\_\_\_\_  
 DOB: \_\_\_\_\_ Gender:  M  F

**Prescriber Information**

Prescriber Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_  
 Fax: \_\_\_\_\_  
 DEA: \_\_\_\_\_ NPI #: \_\_\_\_\_  
 Contact Person: \_\_\_\_\_

**Insurance Information**

Primary Insurance: \_\_\_\_\_ ID#: \_\_\_\_\_ Group: \_\_\_\_\_  
 Secondary Insurance: \_\_\_\_\_ ID#: \_\_\_\_\_ Group: \_\_\_\_\_  
 Prescription Card: \_\_\_\_\_ ID#: \_\_\_\_\_ BIN#: \_\_\_\_\_ PCN#: \_\_\_\_\_ Group: \_\_\_\_\_

**Diagnosis & Lab Work (Fill in below or attach lab work)**

Primary Diagnosis: \_\_\_\_\_ Allergies: \_\_\_\_\_ Previously failed meds: \_\_\_\_\_  
 Expected Date of First/Next Administration: \_\_\_\_\_ Date of Last Administration (if applicable): \_\_\_\_\_  
 Height: \_\_\_\_\_ Weight: \_\_\_\_\_  
 Is the patient up to date on all required labs/vaccinations as required by therapy?  Yes  No

**Please Attach Laboratory Results and Clinical Information.**

**Prescription Information**

Medication	Dose Strength	Directions	Qty	Refills
<input type="checkbox"/> Copaxone <input type="checkbox"/> Glatiramer Acetate <input type="checkbox"/> Glatopa	<input type="checkbox"/> 20mg/mL PFS <input type="checkbox"/> 40mg/mL PFS	<input type="checkbox"/> Inject 20mg SUBQ daily <input type="checkbox"/> Inject 40mg SUBQ three times per week		
Imaavy	<input type="checkbox"/> 300 mg/1.62mL vial <input type="checkbox"/> 1200mg/6.5ml vial	<input type="checkbox"/> <b>Loading Dose:</b> 30mg/kg IV x 1 over ≥ 30 minutes <input type="checkbox"/> <b>Maintenance Dose:</b> (Start 2 weeks after loading dose) 15mg/kg IV q 2 weeks over ≥ 15 minutes		
Kesimpta	<input type="checkbox"/> 20mg/0.4ml Pen	<input type="checkbox"/> <b>Loading Dose:</b> 20mg SUBQ weeks 0, 1, 2. <input type="checkbox"/> <b>Maintenance Dose:</b> 20 mg SUBQ once a month (starting week 4)		
Rystiggo	<input type="checkbox"/> 280mg/2mL vial <input type="checkbox"/> 420mg/3mL vial <input type="checkbox"/> 560mg/4mL vial <input type="checkbox"/> 840mg/6mL vial	<input type="checkbox"/> <b>Loading Dose for weight &lt; 50kg:</b> 420mg SUBQ once weekly x 6 weeks <input type="checkbox"/> <b>Loading Dose for weight ≥ 50 to &lt; 100kg:</b> 560 mg SUBQ once weekly x 6 weeks <input type="checkbox"/> <b>Loading Dose for weight ≥ 100kg:</b> 840 mg SUBQ once weekly x 6 weeks <input type="checkbox"/> <b>Maintenance Dose for weight &lt; 50kg:</b> 420mg SUBQ once weekly x 6 weeks. May repeat 63 days from start of prior treatment cycle. <input type="checkbox"/> <b>Maintenance Dose for weight ≥ 50 to &lt; 100kg:</b> 560mg SUBQ once weekly x 6 weeks. May repeat 63 days from start of prior treatment cycle. <input type="checkbox"/> <b>Maintenance Dose for weight ≥ 100kg:</b> 840 mg SUBQ once weekly x 6 weeks. May repeat 63 days from start of prior treatment cycle.		

**Flush Protocol**

**Premedication** to be given 30 minutes prior to infusion:  
 Acetaminophen PO: 325mg 500 mg 650mg  
 Diphenhydramine: 25 mg IVP 50mg IVP 25mg PO 50mg PO  
**OR** Alternate oral antihistamine: Cetirizine 10mg  Loratadine 10mg  
Fexofenadine 60mgs Fexofenadine 180mgs  
**IV Access Flush Order:** NaCl 0.9% 5-10ml IV before and after infusion  
 Methylprednisolone 125mg IVP 40mg IVP OR \_\_\_mg PO  
Others/Miscellaneous: \_\_\_\_\_

Diphenhydramine Administer 25 mg slow IV/IM may repeat x 1  
**Dispense:** 1 x 50 mg vial  
 Epinephrine Autoinjector  Administer 0.15mg (1:2000) IM (< 30 Kg)  
 Administer 0.3mg (1:1000) IM (≥ 30 Kg)  
**Dispense:** 1 package (2 pens)  
 Sodium Chloride 0.9% *Use to maintain IV line, prevent or treat hypotension in case of anaphylaxis*  
**Dispense:** QS

**Prescriber Signature:** \_\_\_\_\_ **DAW (Dispense as Written)** **Date:** \_\_\_\_\_

*The information contained in this facsimile may be confidential and is intended solely for the use of the name recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intended recipient, please notify us immediately by calling or faxing back to the originator.*

<b>NEUROLOGY REFERRAL FORM</b>	<b>Y Medical Associates</b> <b>Fax : 855-838-0623</b> <b>Phone: 800-447-7558</b>	
Date: _____ <input type="checkbox"/> Current Patient <input type="checkbox"/> New Patient		

Patient Information	Prescriber Information
Patient Name: _____ Address: _____ City, State, Zip: _____ Home Phone: _____ Cell Phone: _____ Alternate Phone: _____ DOB: _____ Gender: <input type="checkbox"/> M <input type="checkbox"/> F	Prescriber Name: _____ Address: _____ City, State, Zip: _____ Phone: _____ Fax: _____ DEA: _____ NPI #: _____ Contact Person: _____

Insurance Information		
Primary Insurance: _____	ID#: _____	Group: _____
Secondary Insurance: _____	ID#: _____	Group: _____
Prescription Card: _____	ID#: _____	BIN#: _____ PCN#: _____ Group: _____

Diagnosis & Lab Work (Fill in below or attach lab work)		
Primary Diagnosis: _____	Allergies: _____	Previously failed meds: _____
Expected Date of First/Next Administration: _____		Date of Last Administration (if applicable): _____
Height: _____	Weight: _____	
Is the patient up to date on all required labs/vaccinations as required by therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No		

**Please Attach Laboratory Results and Clinical Information.**

Prescription Information				
Medication	Dose Strength	Directions	Qty	Refills

Vyvgart	<input type="checkbox"/> 400mg/20mL vial	<input type="checkbox"/> 10mg/kg once weekly x 4 weeks. <input type="checkbox"/> For patients ≥ 120 kg infuse 1200mg/dose <input type="checkbox"/> <b>Subsequent cycle:</b> 10mg/kg (max 1200 mg) IV once weekly x 4 weeks based on clinical evaluation and no sooner than 50 days from start of previous cycle.		
Vyvgart Hytrulo	<input type="checkbox"/> 1000mg-10,000units/5mL PFS  <input type="checkbox"/> 1008mg-11,200 units/5.6ml vials	<b>For MG</b> <input type="checkbox"/> <b>PFS:</b> 1000mg-10,000 units SUBQ over 20-30 seconds weekly x 4 weeks. Subsequent cycles based on clinical evaluation and no sooner than 50 days from start of previous cycle <input type="checkbox"/> <b>Vials:</b> 1008 – 11,200 units SUBQ over 30-90 seconds weekly x 4 weeks. Subsequent cycles based on clinical evaluation and no sooner than 50 days from start of previous cycle. <b>For CIDP</b> <input type="checkbox"/> <b>PFS:</b> 1000mg – 10,000 units SUBQ over 20-30 seconds weekly <input type="checkbox"/> <b>Vials:</b> 1008-11,200 units weekly SUBQ over 30-90 seconds weekly		

Flush Protocol	
<b>Premedication</b> to be given 30 minutes prior to infusion: <input type="checkbox"/> Acetaminophen PO: <input type="checkbox"/> 325mg <input type="checkbox"/> 500 mg <input type="checkbox"/> 650mg Diphenhydramine: <input type="checkbox"/> 25 mg IVP <input type="checkbox"/> 50mg IVP <input type="checkbox"/> 25mg PO <input type="checkbox"/> 50mg PO <b>OR</b> Alternate oral antihistamine: <input type="checkbox"/> Cetirizine 10mg <input type="checkbox"/> Loratadine 10mg <input type="checkbox"/> Fexofenadine 60mgs <input type="checkbox"/> Fexofenadine 180mgs <b>IV Access Flush Order:</b> NaCl 0.9% 5-10ml IV before and after infusion  <input type="checkbox"/> Methylprednisolone <input type="checkbox"/> 125mg IVP <input type="checkbox"/> 40mg IVP OR <input type="checkbox"/> ___mg PO <input type="checkbox"/> Others/Miscellaeous: _____	Diphenhydramine Administer 25 mg slow IV/IM may repeat x 1 <b>Dispense:</b> 1 x 50 mg vial  Epinephrine Autoinjector <input type="checkbox"/> Administer 0.15mg (1:2000) IM (< 30 Kg) <input type="checkbox"/> Administer 0.3mg (1:1000) IM (≥ 30 Kg) <b>Dispense:</b> 1 package (2 pens)  Sodium Chloride 0.9% Use to maintain IV line, prevent or treat hypotension in case of anaphylaxis <b>Dispense:</b> QS

Prescriber Signature: _____	DAW (Dispense as Written) Date: _____
-----------------------------	---------------------------------------

*The information contained in this facsimile may be confidential and is intended solely for the use of the name recipient(s). Access, copying or re-use of the facsimile or any information contained therein by any other person is not authorized. If you are not the intended recipient, please notify us immediately by calling or faxing back to the originator.*